X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Biocon: Statins driving growth… - Views on News from Equitymaster
 
 
  • PRINT
  • E-MAIL
  • FEEDBACK
  • A  A  A
  • May 24, 2004

    Biocon: Statins driving growth…

    India's largest biopharmaceuticals company, Biocon, declared its maiden quarterly and annual results. Since the comparative figures for 4QFY04 are not available, we will focus on the yearly comparison. Total sales of the company has increased by 94% to Rs 5.5 bn while the net profit has risen by 219% to Rs 1.4 bn. Operating profit margin stood at 34% compared to 29%, which is due to better economies of scale. The net profit margin stood at 28% due to lower interest outgo and higher operating margins.

    Results at a glance...
    (Rs m) FY03 FY04 Change
    Net sales 2,539 5,019 97.7%
    Fee income 278 387 39.2%
    Other income 16 87 443.8%
    Expenditure 2,092 3,697 76.7%
    Operating profit (EBDITA) 725 1,709 135.7%
    Operating profit margin (%) 28.6% 34.1%  
    Interest 50 16 -68.0%
    Depreciation 138 163 18.1%
    Profit before tax 553 1,617 192.4%
    Tax 118 231 95.8%
    Profit after tax/(loss) 435 1,386 218.6%
    Net profit margin (%) 17.1% 27.6%  
    No. of shares (m) 100.0 100.0  
    Diluted earnings per share (Rs)* 4.4 13.9  
    P/E ratio (x)   38.5  

    The major growth came from exports (up 150% and 63% of sales) on the back of strong performance by statins and immunosuppressants. Statins are the molecules used for the treatment of cardiovascular disease, which is one of the fastest growing therapeutic segment, both nationally and internationally. The company has gained significant market share in the US and European market as the supplier of off patent statins. Statins, in fact, contribute to 56% of the consolidated revenues of Biocon. The following chart shows the contribution of revenue by statins over last 4 years.

    Its not only the statins that have shown phenomenal growth but also the other segments like anti-diabetics, neutraceuticals, gynecology and anti-osteoporosis have also shown robust growth. The table below gives a perspective on the company's growth in various segments.

    Business segments...
    (Rs m) FY03 FY04 Growth
    BioPharmaceuticals 2,007 4,354 116.9%
    Statins 1,199 3,028 152.5%
    Immunosuppressants 35 137 291.4%
    Others 773 1,189 53.8%
    Enzymes 532 665 25.0%
    Research services 277 387 39.7%
    Custom research 266 385 44.7%
    Clinical research 11 2 -81.8%
    Total 2,816 5,406 92.0%

    The company's plants are USFDA approved, which gives it a chance to expand its market in simvastatin, which will go off patent in the US market from the year 2006. The total size of simvastatin is estimated to be US$ 6 bn. More importantly, the company has signed an agreement with the Bristol Myers Squibb for the supply of recombinant human insulin, which is likely to be in the markets by the 2QFY05.

    On domestic front, Biocon has launched 11 formulations in the cardio-diabetic therapeutic segment under its own brand name. The greater challenge lies in marketing of these products, on which one is likely to have some visibility by the end of 2QFY05.

    The company is very well known for its focus on R&D activities. It spends about 5% of its revenue in R&D activities. Earlier, Biocon focussed on process development but now it is also working towards product development. It has filed 88 patent applications in the FY04. The two entities of the company, which are purely dedicated towards research (including custom research and clinical research), have shown a good performance in FY04. These subsidiaries also provide research services to the third party.

    The stock is currently trading at a P/E of 38.5x FY04 earnings. Though valuations may seem expensive, considering the overall strengths from a long-term perspective, valuations are not high on a relative basis. The new contracts earned and the launch of new drugs in the Indian markets is likely to fuel growth. Also, the year 2006 will be crucial for the company when simvastatin will go off patent in the US markets.

     

     

    Equitymaster requests your view! Post a comment on "Biocon: Statins driving growth…". Click here!

      
     

    More Views on News

    Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

    Jun 23, 2017

    Net Profit lower due to exceptional items in the previous year.

    Biocon: High Other Income And Licensing Income Drive Growth (Quarterly Results Update - Detailed)

    Nov 7, 2016

    Biocon has announced its 2QFY17. The company has reported 19.8% YoY growth in net sales and profits of Rs 1.5 bn for the quarter. Here is our analysis of the results.

    Biocon: Lower R&D Expenses Help Margin Expansion (Quarterly Results Update - Detailed)

    Sep 19, 2016

    Biocon has announced its 1QFY17. The company has reported 21.1% YoY growth in total income and 34.6% YoY increase in net profits. Here is our analysis of the results.

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    More Views on News

    Most Popular

    Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

    Aug 7, 2017

    The data tells us quite a different story from the one the government is trying to project.

    Proxy Plays: A Smart Way to Bet on 'Off Limits' Companies(The 5 Minute Wrapup)

    Aug 4, 2017

    The small-cap space is full of small players that are clear proxies to great growth stories and Indian megatrends.

    Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

    Aug 8, 2017

    Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

    Aug 7, 2017

    Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

    More
    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
     

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms

    BIOCON LTD SHARE PRICE


    Aug 17, 2017 (Close)

    TRACK BIOCON LTD

    • Track your investment in BIOCON LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
    • Add To MyStocks

    BIOCON LTD - ADCOCK INGRAM COMPARISON

    Compare Company With Charts

    COMPARE BIOCON LTD WITH

    MARKET STATS